Targeting the oncogene eIF4E in cancer: From the bench to clinical trials

Clinical and Investigative Medicine

Volumn 34, Issue 6, 2011, Pages

  Borden, Katherine L B ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INITIATION FACTOR 4E; RIBAVIRIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; ONCOGENE; PATHOLOGY;

ANTIVIRAL AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EUKARYOTIC INITIATION FACTOR-4E; HUMANS; LEUKEMIA, MYELOID, ACUTE; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOGENES; RIBAVIRIN;

EID: 84858589998     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Culjkovic, B. and Borden, K.L. (2009). Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer. J Oncol 2009, 981679.
2. Siddiqui, N. and Borden, K.L. (2011) mRNA export and cancer. Wiley Interdiscip Rev RNA. PMID: 21796793. Jul 27. doi: 10.1002/wrna.101.
3. Kentsis, A., Topisirovic, I., Culjkovic, B., Shao, L. and Borden, K.L. (2004). Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A 101, 18105-10.
4. Cohen, N., Sharma, M., Kentsis, A., Perez, J.M., Strudwick, S. and Borden, K.L. (2001). PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO J 20, 4547-59.
5. Kentsis, A., Dwyer, E.C., Perez, J.M., Sharma, M., Chen, A., Pan, Z.Q. and Borden, K.L. (2001). The RING Domains of the Promyelocytic Leukemia Protein PML and the Arenaviral Protein Z Repress Translation by Directly Inhibiting Translation Initiation Factor eIF4E. J Mol Biol 312, 609-23.
6. Kentsis, A., Volpon, L., Topisirovic, I., Soll, C.E., Culjkovic, B., Shao, L. and Borden, K.L. (2005). Further evidence that ribavirin interacts with eIF4E. RNA 11, 1762-6.
7. Borden, K.L.B. and Culjkovic, B. Ribavirin as an anti-cancer therapy: Acute Myeloid Leukemia and Beyond? Leukemia and Lymphoma, Oct;51(10):1805-15
8. Pettersson, F. et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res 17, 2874-84.
9. Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. (2011) Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011 Jul;25(7):1197-1200
10. Tan, K., Culjkovic, B., Amri, A. and Borden, K.L. (2008). Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun 375, 341-5.
11. Topisirovic, I., Guzman, M.L., McConnell, M.J., Licht, J.D., Culjkovic, B., Neering, S.J., Jordan, C.T. and Borden, K.L. (2003). Aberrant eukaryotic translation initiation factor 4Edependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol 23, 8992-9002.
12. Martin, M.G. and Abboud, C.N. (2008). Induction therapy for elderly patients with acute myeloid leukemia. Blood Rev 22, 311-20.
13. Burnett, A., Wetzler, M. and Lowenberg, B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29, 487-94.
14. Assouline, S. et al. (2009). Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood 114, 257-60.
15. Melnick, A. and Licht, J.D. (1999). Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167-215.
16. Zahreddine, H., Kraljacic-Culjkovic, B, Gendron, P, Cormack, G, Borden KLB. (in preparation). Multiple mechanisms of ribavirin resistance.
17. Sidwell, R.W., Huffman, J.H., Khare, G.P., Allen, L.B., Witkowski, J.T. and Robins, R.K. (1972). Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177, 705-6.
18. Cai, J., Damaraju, V.L., Groulx, N., Mowles, D., Peng, Y., Robins, M.J., Cass, C.E. and Gros, P. (2008). Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 68, 2349-57.